ScoreWhy is Apellis Pharmaceuticals, Inc. ?
1
With a growth in Operating Profit of 16.68%, the company declared Outstanding results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 4.49 MM
- NET PROFIT(HY) Higher at USD -134.38 MM
- RAW MATERIAL COST(Y) Fallen by -4.48% (YoY)
2
With ROE of -135.02%, it has a risky valuation with a 14.76 Price to Book Value
- Over the past year, while the stock has generated a return of -34.19%, its profits have risen by 46.9%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Apellis Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Apellis Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Apellis Pharmaceuticals, Inc.
-35.92%
-0.78
63.70%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
276.41%
EBIT Growth (5y)
8.63%
EBIT to Interest (avg)
-15.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0.84
Tax Ratio
0.60%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
14.76
EV to EBIT
-13.55
EV to EBITDA
-13.68
EV to Capital Employed
9.53
EV to Sales
3.25
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-70.33%
ROE (Latest)
-135.02%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 4.49 MM
NET PROFIT(HY)
Higher at USD -134.38 MM
RAW MATERIAL COST(Y)
Fallen by -4.48% (YoY
-9What is not working for the Company
NET PROFIT(HY)
At USD -134.38 MM has Grown at -31.57%
INTEREST(HY)
At USD 22.2 MM has Grown at 35.99%
DEBT-EQUITY RATIO
(HY)
Highest at 62.89 %
Here's what is working for Apellis Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 4.49 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -134.38 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -4.48% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Apellis Pharmaceuticals, Inc.
Net Profit
At USD -134.38 MM has Grown at -31.57%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Interest
At USD 22.2 MM has Grown at 35.99%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 62.89 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
